{"id":"W2591342011","doi":"10.1200/jco.2015.33.28_suppl.117","title":"Invasive disease-free survival benefit following neratinib as extended adjuvant therapy in centrally-confirmed HER2+ early-stage breast cancer: The ExteNET phase III randomized placebo-controlled trial.","year":2015,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Neratinib; Medicine; Placebo; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Population; Breast cancer; Trastuzumab; Randomized controlled trial; Cancer; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001541409,0.001215236,0.002883711,0.0003101725,0.0002594369,0.0008631837,0.0007233873,0.001231532,0.004553891],"category_scores_gemma":[0.001564772,0.0003549866,0.001671949,0.0003670585,0.0006200747,0.0009504161,0.0003588281,0.001905287,0.0005527049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004581694,"about_ca_system_score_gemma":0.0006187624,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003529177,"about_ca_topic_score_gemma":0.001027835,"domain_scores_codex":[0.9994905,0.000271307,0.00003946783,0.00009197959,0.000036052,0.0000706968],"domain_scores_gemma":[0.9994624,0.0001306888,0.0001718589,0.00005247493,0.00003598335,0.0001465821],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9800664,0.002579924,0.0006141687,0.0005412974,0.000779233,0.00004460864,0.00002179964,0.0002838391,0.001552816,0.00009707538,0.000474462,0.01294437],"study_design_scores_gemma":[0.9375028,0.05792708,0.002369646,0.00004433194,0.0006069883,0.00006980269,0.00001922683,0.0003329134,0.0003627472,0.0001736406,0.0005786603,0.00001220029],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844049,0.007889325,0.0006537645,0.0005009275,0.0005401544,0.00231177,0.001125797,0.00009785294,0.002475527],"genre_scores_gemma":[0.9905558,0.002217305,0.0008739035,0.0006196508,0.0003665084,0.001904194,0.001315695,0.00001423605,0.002132647],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004553891,"threshold_uncertainty_score":0.01523423,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1482590249627394,"score_gpt":0.4963269494320232,"score_spread":0.3480679244692838,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}